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Background
Oral immunotherapy is an emerging therapy currently
under investigation for the treatment of food allergy [1].
Underlying mechanisms are thought to involve a switch in
the food specific T cell response from Th2 to either Th1,
Tr1 and/or Treg. It is unknown whether this change in
response results from re-education of existing pathological
food-specific T cells or from their replacement by new
healthy T cells (change of guard hypothesis).
Methods
The objective was to evaluate the clonal distribution of
peanut specific T cell in subjects with peanut allergy
and follow changes in clonotype with treatment using a
high-throughput T cell receptor (TCR) sequencing plat-
form. Peripheral blood mononuclear cells (PBMCs)
from three subjects undergoing rush oral immunother-
apy in a previous trial [2] and three control subjects on
avoidance diet were cultured with peanut extract at
baseline and at 9 and 18 months. Carboxyfluorescein
succinimidyl ester (CFSE)-low peanut proliferating
T cells were then isolated by fluorescence-activated cell
sorting (FACS) and TCR analysis was performed.
Results
The CFSE-low proliferating fraction was found to be
comprised of between 2000 and 12,000 different T cell
clones. However, only between 15 and 25% of proliferat-
ing T cells (from 100-400 different clones) were consis-
tently found at all three time points and probably
represented true peanut-specific T cells. While the
relative frequency of these peanut-specific clones was
stable over time in subjects on avoidance diet (R=0.633
to 0.760), it was found to change in subjects undergoing
oral immunotherapy (R= 0.123 to 0.350), following two
characteristic patterns.
Conclusions
Using a deep TCR sequencing platform, we found that
only a fraction of CFSE-low peanut proliferating T cells
were consistent in time and likely to represent true peanut
specific T cells. Oral immunotherapy was associated with
changes in relative frequency of clones within this fraction,
which would support the change of guard hypothesis.
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